A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Memantine

Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.

DRUG

Placebo

Trial Locations (2)

10029

Mount Sinai School of Medicine, New York

60612

Rush University Medical Center, Chicago

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Rush University Medical Center

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

Evdokia Anagnostou

INDIV

NCT01372449 - A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM) | Biotech Hunter | Biotech Hunter